Potential molecular mechanism of Cangshu guiding phlegm pill in the treatment of T2DM based on metabolic abnormality diagnosis: detection of key biomarkers

BACKGROUND AND PURPOSE: This study, based on the network pharmacology approach, aims to systematically explore the potential molecular mechanism of Cangshu Diantong Pill in treating type 2 diabetes (T2DM), and particularly emphasises the theoretical correlation between its mechanism of action and the modern metabolic abnormality diagnostic indicators. METHODS: The study first screened the active components in Cangshu Diantong Pill that have pharmacokinetic characteristics through databases such as TCMIP, it integrated disease databases to obtain T2DM-related targets and constructed a drug-disease intersection target network. Core targets included AKT2, TNF, ADIPOQ, IGF1, etc., all of which are key biomarkers in current metabolic abnormality diagnostics. RESULTS: Pathway enrichment showed that Cangshu Diantong Pill mainly exerts its effects by regulating signalling pathways. CONCLUSION: The study suggests that Cangshu Diantong Pill's intervention on T2DM may manifest as a synergistic regulation of multiple metabolic abnormality links, and its theoretical action pathway is highly consistent with the modern metabolic diagnostic system.